118 related articles for article (PubMed ID: 38237304)
1. Tozasertib activates anti-tumor immunity through decreasing regulatory T cells in melanoma.
Wang Q; Liu W; Zhou H; Lai W; Hu C; Dai Y; Li G; Zhang R; Zhao Y
Neoplasia; 2024 Feb; 48():100966. PubMed ID: 38237304
[TBL] [Abstract][Full Text] [Related]
2. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.
Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M
Front Immunol; 2022; 13():794684. PubMed ID: 35720386
[TBL] [Abstract][Full Text] [Related]
3. MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma.
de Azevedo RA; Shoshan E; Whang S; Markel G; Jaiswal AR; Liu A; Curran MA; Travassos LR; Bar-Eli M
Oncoimmunology; 2020 Dec; 9(1):1846915. PubMed ID: 33344042
[TBL] [Abstract][Full Text] [Related]
4. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.
Cooper ZA; Juneja VR; Sage PT; Frederick DT; Piris A; Mitra D; Lo JA; Hodi FS; Freeman GJ; Bosenberg MW; McMahon M; Flaherty KT; Fisher DE; Sharpe AH; Wargo JA
Cancer Immunol Res; 2014 Jul; 2(7):643-54. PubMed ID: 24903021
[TBL] [Abstract][Full Text] [Related]
5. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
6. Aiduqing formula inhibits breast cancer metastasis by suppressing TAM/CXCL1-induced Treg differentiation and infiltration.
Li J; Wang S; Wang N; Zheng Y; Yang B; Wang X; Zhang J; Pan B; Wang Z
Cell Commun Signal; 2021 Aug; 19(1):89. PubMed ID: 34461944
[TBL] [Abstract][Full Text] [Related]
7. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
8. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
9. Blockade of MIF-CD74 Signalling on Macrophages and Dendritic Cells Restores the Antitumour Immune Response Against Metastatic Melanoma.
Figueiredo CR; Azevedo RA; Mousdell S; Resende-Lara PT; Ireland L; Santos A; Girola N; Cunha RLOR; Schmid MC; Polonelli L; Travassos LR; Mielgo A
Front Immunol; 2018; 9():1132. PubMed ID: 29875777
[TBL] [Abstract][Full Text] [Related]
10. Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells.
Noyes D; Bag A; Oseni S; Semidey-Hurtado J; Cen L; Sarnaik AA; Sondak VK; Adeegbe D
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35618289
[TBL] [Abstract][Full Text] [Related]
11. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
[TBL] [Abstract][Full Text] [Related]
12. CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma.
Bozhanova G; Hassan J; Appleton L; Jennings V; Foo S; McLaughlin M; Chan Wah Hak CM; Patin EC; Crespo-Rodriguez E; Baker G; Armstrong E; Chiu M; Pandha H; Samson A; Roulstone V; Kyula J; Vile R; Errington-Mais F; Pedersen M; Harrington K; Ono M; Melcher A
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338089
[TBL] [Abstract][Full Text] [Related]
13. Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1.
Imbert C; Montfort A; Fraisse M; Marcheteau E; Gilhodes J; Martin E; Bertrand F; Marcellin M; Burlet-Schiltz O; Peredo AG; Garcia V; Carpentier S; Tartare-Deckert S; Brousset P; Rochaix P; Puisset F; Filleron T; Meyer N; Lamant L; Levade T; Ségui B; Andrieu-Abadie N; Colacios C
Nat Commun; 2020 Jan; 11(1):437. PubMed ID: 31974367
[TBL] [Abstract][Full Text] [Related]
14. CD4
Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
[TBL] [Abstract][Full Text] [Related]
15. LAG3 and TIGIT Expression on Tumor-Infiltrating Lymphocytes in Cutaneous Melanoma.
Naimy S; Bzorek M; Eriksen JO; Løvendorf MB; Litman T; Dyring-Andersen B; Gjerdrum LMR
Dermatology; 2024; 240(1):156-163. PubMed ID: 37952520
[TBL] [Abstract][Full Text] [Related]
16. Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors.
Ding L; Sun L; Bu MT; Zhang Y; Scott LN; Prins RM; Su MA; Lechner MG; Hugo W
Front Immunol; 2023; 14():1176994. PubMed ID: 37435085
[TBL] [Abstract][Full Text] [Related]
17. Activated CTLA-4-independent immunosuppression of Treg cells disturbs CTLA-4 blockade-mediated antitumor immunity.
Watanabe T; Ishino T; Ueda Y; Nagasaki J; Sadahira T; Dansako H; Araki M; Togashi Y
Cancer Sci; 2023 May; 114(5):1859-1870. PubMed ID: 36762794
[TBL] [Abstract][Full Text] [Related]
18. Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8
Tada Y; Togashi Y; Kotani D; Kuwata T; Sato E; Kawazoe A; Doi T; Wada H; Nishikawa H; Shitara K
J Immunother Cancer; 2018 Oct; 6(1):106. PubMed ID: 30314524
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.
Spranger S; Spaapen RM; Zha Y; Williams J; Meng Y; Ha TT; Gajewski TF
Sci Transl Med; 2013 Aug; 5(200):200ra116. PubMed ID: 23986400
[TBL] [Abstract][Full Text] [Related]
20. Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity.
Punt S; Malu S; McKenzie JA; Manrique SZ; Doorduijn EM; Mbofung RM; Williams L; Silverman DA; Ashkin EL; Dominguez AL; Wang Z; Chen JQ; Maiti SN; Tieu TN; Liu C; Xu C; Forget MA; Haymaker C; Khalili JS; Satani N; Muller F; Cooper LJN; Overwijk WW; Amaria RN; Bernatchez C; Heffernan TP; Peng W; Roszik J; Hwu P
Cancer Immunol Immunother; 2021 Apr; 70(4):1101-1113. PubMed ID: 33123754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]